相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth
Yin-Hsun Feng et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2011)
Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case-control study
M. C. Bradley et al.
BRITISH JOURNAL OF CANCER (2010)
The reactive tumor microenvironment: MUC1 signaling directly reprograms transcription of CTGF
M. E. Behrens et al.
ONCOGENE (2010)
Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes
Sudarshan K. Vijay et al.
ACTA DIABETOLOGICA (2009)
Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma
Fei Zhao et al.
IMMUNOLOGY (2009)
Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice
Hanh K. Le et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2009)
Progression of Pancreatic Adenocarcinoma Is Significantly Impeded with a Combination of Vaccine and COX-2 Inhibition
Pinku Mukherjee et al.
JOURNAL OF IMMUNOLOGY (2009)
The Immune Tolerance of Cancer is Mediated by IDO That is Inhibited by COX-2 Inhibitors Through Regulatory T Cells
Sling Yong Lee et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer
J. M. Bailey et al.
ONCOGENE (2009)
Rosiglitazone and risk of cancer - A meta-analysis of randomized clinical trials
Matteo Monami et al.
DIABETES CARE (2008)
Toll-like receptor 4 mediates cross-talk between peroxisome proliferator-activated receptor γ and nuclear factor-κB in macrophages
Brian M. Necela et al.
IMMUNOLOGY (2008)
Phosphorylation of MUC1 by met modulates interaction with p53 and MMP1 expression
Pankaj K. Singh et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Effect of Celecoxib and the Novel Anti-Cancer Agent, Dimethylamino-Parthenolide, in a Developmental Model of Pancreatic Cancer
Michele T. Yip-Schneider et al.
PANCREAS (2008)
Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase
Saswati Hazra et al.
MOLECULAR PHARMACOLOGY (2007)
Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells
Pratima Sinha et al.
CANCER RESEARCH (2007)
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes
Rangaswamy Govindarajan et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor-γ
Yan-Qin Zhang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor γ agonist treatment
Christian Grommes et al.
MOLECULAR PHARMACOLOGY (2006)
Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinorna and its premalignant lesions
Nobuyoshi Hiraoka et al.
CLINICAL CANCER RESEARCH (2006)
Peroxisome proliferator-activated receptor γ (PPAR-γ) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer
Jo A. Van Ginderachter et al.
BLOOD (2006)
RNA interference suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells
Hideaki Tsutsumida et al.
CLINICAL CANCER RESEARCH (2006)
The role of the peroxisome proliferator-activated receptor-α (PPAR-α) in the regulation of acute inflammation
Salvatore Cuzzocrea et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2006)
Activation of peroxisome proliferator-activated receptor-γ decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system
H Sawai et al.
MOLECULAR CANCER RESEARCH (2006)
Rosiglitazone suppresses human lung carcinoma cell growth through PPAR-γ-dependent and PPARγ-independent signal pathways
SW Han et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial
V Ferrari et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression
SK Bunt et al.
JOURNAL OF IMMUNOLOGY (2006)
Inhibition of bladder tumor growth by 1,1-bis(3 '-indolyl)-1-(p-substitutedphenyl)methanes: A new class of peroxisome proliferator-activated receptor gamma agonists
W Kassouf et al.
CANCER RESEARCH (2006)
Pioglitazone induces vascular smooth muscle cell apoptosis through a peroxisome proliferator-activated receptor-γ, transforming growth factor-β1, and a Smad2-dependent mechanism
S Redondo et al.
DIABETES (2005)
Rosiglitazone works synergistically with gemcitabine to induce cell death in pancreas cancer cell lines.
AN Salesiotis et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Peroxisome-proliferator-activated receptors and cancers: Complex stories
L Michalik et al.
NATURE REVIEWS CANCER (2004)
Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARγ independent mechanisms
A Galli et al.
GUT (2004)
Comparison of the effects of pioglitazone and rosiglitazone on macrophage foam cell formation
M Hirakata et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Inflammatory mechanisms contributing to pancreatic cancer development
B Farrow et al.
ANNALS OF SURGERY (2004)
Emerging roles of PPARs in inflammation and immunity
RA Daynes et al.
NATURE REVIEWS IMMUNOLOGY (2002)
Ligands for peroxisome proliferator-activated receptor γ inhibit growth of pancreatic cancers both in vitro and in vivo
A Itami et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Inflammation and cancer: back to Virchow?
F Balkwill et al.
LANCET (2001)
Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation
SA Kusmartsev et al.
JOURNAL OF IMMUNOLOGY (2000)
分享论文
